Jiali Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiali Hu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Dingjie Liu
Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China
1 shared publicationGuang Yang
Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China
1 shared publication- Guihai Zhang
Department of Oncology, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), The Affiliated Hospital of Beijing Institute of Technology, Zhuhai 519000, China
1 shared publication - Haihai Liang
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Labratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China
1 shared publication Haihong Lei
Department of Radiation Oncology, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China
1 shared publication- Hong-Wei Sun
Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University); School of Bioengineering, Zunyi Medical University, Zhuhai, China
1 shared publication
Latest Publications
- Open Access
- 25 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (11) , 3005-3025
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity, specifically in the context of CD8 + T-cell antitumour immunity, remains unclear. Here, we demonstrate that RIG-I is upregulated in tumour-infiltrating CD8 + T cells, where it functions as an intracellular checkpoint to negatively regulate CD8 + T-cell function and limit antitumour immunity. Mechanistically, the upregulation of RIG-I in CD8 + T cells is induced by activated T cells, and directly inhibits the AKT/glycolysis signalling pathway. In addition, knocking out RIG-I enhances the efficacy of adoptively transferred T cells against solid tumours, and inhibiting RIG-I enhances the response to PD-1 blockade. Overall, our study identifies RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with an immune checkpoint inhibitor.
- 25 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (11) , 3005-3025
Open AccessRIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity, specifically in the context of CD8 + T-cell antitumour immunity, remains unclear. Here, we demonstrate that RIG-I is upregulated in tumour-infiltrating CD8 + T cells, where it functions as an intracellular checkpoint to negatively regulate CD8 + T-cell function and limit antitumour immunity. Mechanistically, the upregulation of RIG-I in CD8 + T cells is induced by activated T cells, and directly inhibits the AKT/glycolysis signalling pathway. In addition, knocking out RIG-I enhances the efficacy of adoptively transferred T cells against solid tumours, and inhibiting RIG-I enhances the response to PD-1 blockade. Overall, our study identifies RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with an immune checkpoint inhibitor.